Used in the treatment of certain B-cell non-Hodgkin's lymphomas, this antibody targets CD20 antigens on the surface of malignant and normal B cells, leading to cell destruction through mechanisms such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis. It serves as a reference standard in the development and validation of biosimilar antibodies and diagnostic assays. Commonly employed in radiolabeled form in clinical and research settings to evaluate binding affinity, pharmacokinetics, and biodistribution. Supports quality control in manufacturing processes for monoclonal antibody products targeting CD20.